Zacks Small Cap Has Positive Outlook for TNXP Q2 Earnings

Key Points

• Zacks Small Cap has increased its Q2 2025 earnings per share estimate for Tonix Pharmaceuticals to ($3.51), significantly improving from the previous estimate of ($10.73).
• Tonix Pharmaceuticals reported earnings of (2.84) per share for its last quarter, surpassing analysts' expectations of (3.23) by $0.39.
• Insider activity includes CEO Seth Lederman purchasing 4,000 shares at an average cost of $21.55 per share, marking an 80,000% increase in his position.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Zacks Small Cap boosted their Q2 2025 earnings per share estimates for Tonix Pharmaceuticals in a note issued to investors on Tuesday, July 29th. Zacks Small Cap analyst D. Bautz now expects that the company will earn ($3.51) per share for the quarter, up from their previous estimate of ($10.73). The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($1,762.50) per share. Zacks Small Cap also issued estimates for Tonix Pharmaceuticals' Q3 2025 earnings at ($3.24) EPS, Q4 2025 earnings at ($3.91) EPS and FY2025 earnings at ($13.68) EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($2.84) EPS for the quarter, beating the consensus estimate of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative return on equity of 120.96% and a negative net margin of 1,313.87%. The company had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.55 million.

Several other brokerages have also recently issued reports on TNXP. Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Alliance Global Partners reiterated a "buy" rating on shares of Tonix Pharmaceuticals in a research note on Tuesday, June 3rd.

Tonix Pharmaceuticals Stock Up 3.5%

Shares of Tonix Pharmaceuticals stock traded up $1.33 on Thursday, hitting $39.01. The stock had a trading volume of 1,271,149 shares, compared to its average volume of 1,362,876. The stock has a market cap of $287.11 million, a price-to-earnings ratio of -0.02 and a beta of 1.70. The business's 50 day moving average is $38.84 and its two-hundred day moving average is $25.97. Tonix Pharmaceuticals has a twelve month low of $6.76 and a twelve month high of $130.00.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in TNXP. Commonwealth Equity Services LLC bought a new stake in Tonix Pharmaceuticals during the fourth quarter worth $40,000. Two Sigma Investments LP bought a new stake in Tonix Pharmaceuticals during the fourth quarter worth $66,000. Northern Trust Corp bought a new stake in Tonix Pharmaceuticals during the fourth quarter worth $162,000. IFP Advisors Inc bought a new stake in Tonix Pharmaceuticals during the first quarter worth $179,000. Finally, Rhumbline Advisers bought a new stake in Tonix Pharmaceuticals during the first quarter worth $244,000. 82.26% of the stock is currently owned by institutional investors.

Insider Activity

In other Tonix Pharmaceuticals news, CEO Seth Lederman bought 4,000 shares of the business's stock in a transaction on Thursday, May 15th. The stock was purchased at an average cost of $21.55 per share, for a total transaction of $86,200.00. Following the completion of the purchase, the chief executive officer directly owned 4,005 shares of the company's stock, valued at approximately $86,307.75. This trade represents a 80,000.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.03% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.